{"id":"pf-02341066","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Vision disorders"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug inhibits ALK and ROS1 receptor tyrosine kinases, which are frequently dysregulated in certain cancers through gene fusions or mutations. By blocking these kinases, PF-02341066 prevents downstream signaling that drives cancer cell proliferation and survival. This mechanism is particularly effective in ALK-positive and ROS1-positive non-small cell lung cancers.","oneSentence":"PF-02341066 is a tyrosine kinase inhibitor that targets ALK (anaplastic lymphoma kinase) and ROS1 to block aberrant signaling in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:55.015Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"ALK-positive non-small cell lung cancer"},{"name":"ROS1-positive non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":720},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8","enrollment":8300},{"nctId":"NCT06360575","phase":"PHASE2","title":"Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-07-20","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":20},{"nctId":"NCT03737994","phase":"PHASE2","title":"Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-25","conditions":"Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":10},{"nctId":"NCT06357975","phase":"PHASE2","title":"Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-07-29","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":44},{"nctId":"NCT02838420","phase":"PHASE3","title":"A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2016-08-03","conditions":"Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer","enrollment":187},{"nctId":"NCT04693468","phase":"PHASE1","title":"Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-01","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm","enrollment":111},{"nctId":"NCT04283669","phase":"PHASE2","title":"Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2020-02-18","conditions":"Neurofibromatosis 2, Progressive Vestibular Schwannoma (VS)","enrollment":12},{"nctId":"NCT02568267","phase":"PHASE2","title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2015-11-19","conditions":"Breast Cancer, Cholangiocarcinoma, Colorectal Cancer","enrollment":534},{"nctId":"NCT04603807","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-09-30","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":220},{"nctId":"NCT03194893","phase":"PHASE3","title":"A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-07-05","conditions":"Neoplasms","enrollment":200},{"nctId":"NCT05987332","phase":"PHASE2, PHASE3","title":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"IDEAYA Biosciences","startDate":"2023-10-31","conditions":"Metastatic Uveal Melanoma","enrollment":420},{"nctId":"NCT03947385","phase":"PHASE1, PHASE2","title":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions","status":"RECRUITING","sponsor":"IDEAYA Biosciences","startDate":"2019-06-28","conditions":"Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer","enrollment":336},{"nctId":"NCT05297890","phase":"PHASE2","title":"A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2022-05-27","conditions":"Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer","enrollment":70},{"nctId":"NCT02201992","phase":"PHASE3","title":"Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2015-03-23","conditions":"ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive","enrollment":166},{"nctId":"NCT03052608","phase":"PHASE3","title":"A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2017-04-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":296},{"nctId":"NCT06140836","phase":"PHASE3","title":"A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-12-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":190},{"nctId":"NCT06564324","phase":"PHASE3","title":"A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients","status":"RECRUITING","sponsor":"Nuvation Bio Inc.","startDate":"2024-11-27","conditions":"Non Small Cell Lung Cancer","enrollment":138},{"nctId":"NCT04439266","phase":"PHASE2","title":"Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-12","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":5},{"nctId":"NCT03620643","phase":"PHASE2","title":"Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours","status":"COMPLETED","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2019-05-09","conditions":"Lobular Breast Carcinoma, Gastric Cancer, Triple Negative Breast Cancer","enrollment":33},{"nctId":"NCT05384626","phase":"PHASE1, PHASE2","title":"A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)","status":"RECRUITING","sponsor":"Nuvalent Inc.","startDate":"2022-06-09","conditions":"Locally Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":840},{"nctId":"NCT02767804","phase":"PHASE3","title":"eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xcovery Holdings, Inc.","startDate":"2016-06","conditions":"Non-small Cell Lung Cancer","enrollment":290},{"nctId":"NCT07207278","phase":"","title":"Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma","status":"RECRUITING","sponsor":"First People's Hospital of Hangzhou","startDate":"2025-09-01","conditions":"Signet Ring Cell Carcinoma of the Lung","enrollment":39},{"nctId":"NCT04439253","phase":"PHASE2","title":"Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-12","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":4},{"nctId":"NCT03596866","phase":"PHASE3","title":"A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"Takeda","startDate":"2019-04-19","conditions":"ALK+ Advanced NSCLC","enrollment":248},{"nctId":"NCT05160922","phase":"PHASE4","title":"Crizotinib Continuation Clinical Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2021-12-27","conditions":"NSCLC, ALCL, IMT","enrollment":27},{"nctId":"NCT02075840","phase":"PHASE3","title":"A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-08-19","conditions":"Non-Small Cell Lung Cancer","enrollment":303},{"nctId":"NCT04030429","phase":"PHASE2","title":"Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer","status":"TERMINATED","sponsor":"National Cheng-Kung University Hospital","startDate":"2019-09-01","conditions":"Endometrial Cancer Recurrent","enrollment":40},{"nctId":"NCT05195619","phase":"PHASE1","title":"Personalized DC Vaccines in Non Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2022-03-22","conditions":"Non-small Cell Lung Cancer","enrollment":16},{"nctId":"NCT03375242","phase":"","title":"Safety and Efficacy of Xalkori ROS1","status":"RECRUITING","sponsor":"Pfizer","startDate":"2017-10-25","conditions":"Non-small Cell Lung Cancer","enrollment":100},{"nctId":"NCT02664935","phase":"PHASE2","title":"National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Birmingham","startDate":"2015-05","conditions":"Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell, Adenocarcinoma","enrollment":423},{"nctId":"NCT06082635","phase":"PHASE3","title":"TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2023-12-14","conditions":"Non Small Cell Lung Cancer","enrollment":321},{"nctId":"NCT06214793","phase":"PHASE2","title":"Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)","status":"SUSPENDED","sponsor":"Megan Kruse, MD","startDate":"2026-04","conditions":"Breast Cancer, Metastatic Breast Cancer","enrollment":61},{"nctId":"NCT05834348","phase":"","title":"A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-23","conditions":"Non-Small Cell Lung Cancer","enrollment":5279},{"nctId":"NCT04423185","phase":"PHASE2","title":"PLATFORM Study of Precision Medicine for Rare Tumors","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-08-15","conditions":"Rare Tumor","enrollment":770},{"nctId":"NCT01828112","phase":"PHASE3","title":"LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-06-28","conditions":"Non-Small Cell Lung Cancer","enrollment":231},{"nctId":"NCT01121588","phase":"PHASE1","title":"Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2011-03-22","conditions":"Neoplasms Malignant","enrollment":44},{"nctId":"NCT02761057","phase":"PHASE2","title":"Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2016-07-25","conditions":"Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7","enrollment":152},{"nctId":"NCT06563999","phase":"PHASE2","title":"Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-01","conditions":"Lung Cancer Stage III, Mutation","enrollment":120},{"nctId":"NCT00828919","phase":"NA","title":"Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-03-07","conditions":"Solid Tumors","enrollment":52},{"nctId":"NCT06694129","phase":"","title":"Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Center, China","startDate":"2024-12-01","conditions":"Non-Small Cell Lung Cancer, ROS1 Gene Rearrangement, Resistance","enrollment":40},{"nctId":"NCT03672643","phase":"PHASE4","title":"Long Term Safety Observation of Crizotinib in Chinese NSCLC Population","status":"TERMINATED","sponsor":"Pfizer","startDate":"2019-01-28","conditions":"ALK or ROS1-positive NSCLC","enrollment":41},{"nctId":"NCT04322890","phase":"PHASE2","title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2020-04-16","conditions":"Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation","enrollment":6000},{"nctId":"NCT06196814","phase":"PHASE1, PHASE2","title":"AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2024-10-01","conditions":"Efficacy","enrollment":150},{"nctId":"NCT03718117","phase":"","title":"Descriptive Observational Study ALK-2016-CPHG","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-01-03","conditions":"NSCLC, Crizotinib, ALK Gene Rearrangement or ROS1 Gene Rearrangement","enrollment":73},{"nctId":"NCT05014464","phase":"PHASE2","title":"ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2021-11-13","conditions":"Non-small Cell Lung Cancer","enrollment":90},{"nctId":"NCT06569420","phase":"PHASE3","title":"Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","startDate":"2021-12-31","conditions":"Non-Small Cell Lung Cancer, ALK-positive, SAF-189s","enrollment":275},{"nctId":"NCT01970865","phase":"PHASE1, PHASE2","title":"A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-01-08","conditions":"ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC","enrollment":364},{"nctId":"NCT02679170","phase":"","title":"Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-06-29","conditions":"Non-Small Cell Lung Cancer","enrollment":692},{"nctId":"NCT01712217","phase":"PHASE1, PHASE2","title":"A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2012-10","conditions":"Non-small Cell Lung Cancer(NSCLC)","enrollment":220},{"nctId":"NCT04084717","phase":"PHASE2","title":"Study of Crizotinib for ROS1 and MET Activated Lung Cancer","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2019-12-03","conditions":"Non-squamous Non-small-cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, ROS1 Gene Rearrangement","enrollment":50},{"nctId":"NCT03546894","phase":"","title":"A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-07-23","conditions":"Anaplastic Lymphoma Kinase-positive, Carcinoma Non-small-cell Lung","enrollment":111},{"nctId":"NCT02473497","phase":"","title":"Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients","status":"NO_LONGER_AVAILABLE","sponsor":"Pfizer","startDate":"","conditions":"Neoplasm","enrollment":""},{"nctId":"NCT04322578","phase":"PHASE2","title":"Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2020-03-24","conditions":"Non-small Cell Lung Cancer","enrollment":120},{"nctId":"NCT01979536","phase":"PHASE2","title":"Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-11-13","conditions":"Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma","enrollment":137},{"nctId":"NCT04211922","phase":"PHASE2","title":"Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib","status":"TERMINATED","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2020-01-21","conditions":"ALK-positive Non-small Cell Lung Cancer","enrollment":4},{"nctId":"NCT03607188","phase":"PHASE1","title":"Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2018-10-18","conditions":"Non-small Cell Lung Cancer","enrollment":17},{"nctId":"NCT02034981","phase":"PHASE2","title":"Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2013-08","conditions":"Hematologic Cancers, Solid Tumors, Metastatic Cancer","enrollment":246},{"nctId":"NCT06254599","phase":"PHASE3","title":"A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Shouyao Holdings (Beijing) Co. LTD","startDate":"2024-05-01","conditions":"Non-small Cell Lung Cancer","enrollment":255},{"nctId":"NCT02925234","phase":"PHASE2","title":"The Drug Rediscovery Protocol (DRUP Trial)","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2016-08","conditions":"Cancer, Tumors, Neoplasm","enrollment":1550},{"nctId":"NCT01606878","phase":"PHASE1","title":"Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2013-04-29","conditions":"Childhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Neuroblastoma","enrollment":46},{"nctId":"NCT03647111","phase":"","title":"Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Hunan Province Tumor Hospital","startDate":"2018-01-01","conditions":"Non-small Cell Lung Cancer","enrollment":120},{"nctId":"NCT03646994","phase":"","title":"Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Hunan Province Tumor Hospital","startDate":"2018-08-01","conditions":"Non-small Cell Lung Cancer","enrollment":40},{"nctId":"NCT01524926","phase":"PHASE2","title":"CREATE: Cross-tumoral Phase 2 With Crizotinib","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2012-09","conditions":"Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor, Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1","enrollment":582},{"nctId":"NCT02223819","phase":"PHASE2","title":"Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy","status":"COMPLETED","sponsor":"Columbia University","startDate":"2015-03","conditions":"Uveal Melanoma","enrollment":34},{"nctId":"NCT04632758","phase":"PHASE3","title":"Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2019-06-01","conditions":"Non-small Cell Lung Cancer","enrollment":292},{"nctId":"NCT04148066","phase":"NA","title":"ctDNA Guided Treatment of Early Resistance to Targeted Treatment","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2019-07-17","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":104},{"nctId":"NCT03215693","phase":"PHASE2","title":"X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2017-09-28","conditions":"Non-Small Cell Lung Cancer","enrollment":152},{"nctId":"NCT02584634","phase":"PHASE1, PHASE2","title":"Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2015-12-18","conditions":"Non-Small Cell Lung Cancer","enrollment":43},{"nctId":"NCT01744652","phase":"PHASE1","title":"Dasatinib and Crizotinib in Advanced Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-03","conditions":"Advanced Cancers","enrollment":62},{"nctId":"NCT02727335","phase":"","title":"Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2014-05","conditions":"Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase Gene Mutation","enrollment":318},{"nctId":"NCT04647110","phase":"","title":"Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-12-14","conditions":"ALK-positive NSCLC","enrollment":549},{"nctId":"NCT05792644","phase":"NA","title":"Therapeutic Effect of Crizotinib for Rearrangement-negative, High Phosphorylated ALK Patients","status":"COMPLETED","sponsor":"Harbin Medical University","startDate":"2018-01-01","conditions":"ALK Phosphorylation","enrollment":15},{"nctId":"NCT02419287","phase":"PHASE2","title":"Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas","status":"COMPLETED","sponsor":"University of Milano Bicocca","startDate":"2015-04","conditions":"Anaplastic Large Cell Lymphoma, ALK-Positive","enrollment":12},{"nctId":"NCT05725200","phase":"PHASE2","title":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2022-09-27","conditions":"Metastatic Colorectal Cancer","enrollment":40},{"nctId":"NCT00585195","phase":"PHASE1","title":"A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-04-19","conditions":"Non-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer c-Met Dependent, Non-Small Cell Lung Cancer ROS Marker Positive","enrollment":596},{"nctId":"NCT03574402","phase":"PHASE2","title":"Phase II Umbrella Study Directed by Next Generation Sequencing","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2018-07-09","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":400},{"nctId":"NCT02612194","phase":"PHASE2","title":"LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2016-09-27","conditions":"Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms","enrollment":8},{"nctId":"NCT04634110","phase":"PHASE2","title":"Brigatinib Before Brain Irradiation Trial (B3i Trial)","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2020-11-17","conditions":"Brain Metastases, Lung Cancer","enrollment":1},{"nctId":"NCT05467189","phase":"","title":"Antineoplastic Drugs in Elderly Patients","status":"RECRUITING","sponsor":"Shandong University","startDate":"2021-01-01","conditions":"Cancer","enrollment":500},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT02183870","phase":"PHASE2","title":"EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2014-05","conditions":"Lung Cancer, Adenocarcinoma, NSCLC","enrollment":34},{"nctId":"NCT02270034","phase":"PHASE1","title":"Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"Grupo Español de Investigación en Neurooncología","startDate":"2014-08-13","conditions":"Glioblastoma Multiforme (Grade IV) of Cerebellum","enrollment":38},{"nctId":"NCT03088930","phase":"PHASE2","title":"Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-12-13","conditions":"Lung Cancer, Nonsmall Cell","enrollment":3},{"nctId":"NCT05204628","phase":"PHASE3","title":"A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib","status":"UNKNOWN","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2022-02-07","conditions":"Non-small Cell Lung Cancer","enrollment":238},{"nctId":"NCT04856293","phase":"PHASE1","title":"Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-04-16","conditions":"Healthy Participants","enrollment":25},{"nctId":"NCT02207504","phase":"PHASE1","title":"Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-08","conditions":"Castration-resistant Prostate Cancer","enrollment":24},{"nctId":"NCT05063058","phase":"NA","title":"Biomarker-driven Therapy for Melanoma","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2016-01","conditions":"Melanoma","enrollment":100},{"nctId":"NCT01548144","phase":"PHASE1","title":"Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-04","conditions":"Advanced Cancers","enrollment":178},{"nctId":"NCT02737501","phase":"PHASE3","title":"ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants","status":"COMPLETED","sponsor":"Ariad Pharmaceuticals","startDate":"2016-05-26","conditions":"Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies","enrollment":275},{"nctId":"NCT03439215","phase":"PHASE2","title":"PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer","status":"UNKNOWN","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2017-06-13","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":20},{"nctId":"NCT02510001","phase":"PHASE1","title":"MEK and MET Inhibition in Colorectal Cancer","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-11","conditions":"Solid Tumor, Colorectal Cancer","enrollment":82},{"nctId":"NCT02574078","phase":"PHASE1, PHASE2","title":"A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-11-23","conditions":"Non-Small Cell Lung Cancer","enrollment":341},{"nctId":"NCT02094573","phase":"PHASE2","title":"A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib","status":"COMPLETED","sponsor":"Ariad Pharmaceuticals","startDate":"2014-06-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":222},{"nctId":"NCT04292119","phase":"PHASE1, PHASE2","title":"Lorlatinib Combinations in Lung Cancer","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","startDate":"2020-05-01","conditions":"Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation, ROS1 Rearrangement","enrollment":96},{"nctId":"NCT01945021","phase":"PHASE2","title":"Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-09-30","conditions":"Non Small Cell Lung Cancer, ROS1 Proto Oncogene, Crizotinib","enrollment":129},{"nctId":"NCT01531361","phase":"PHASE1","title":"Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-02-06","conditions":"Advanced Malignant Neoplasm, BRAF Gene Mutation, Metastatic Malignant Neoplasm","enrollment":46},{"nctId":"NCT01300429","phase":"","title":"Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-02-08","conditions":"Lung Cancer","enrollment":30},{"nctId":"NCT01579994","phase":"PHASE1","title":"Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-04-16","conditions":"Advanced Lung Cancer","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["cMET inhibitor","Crizotinib","crizotinib"],"phase":"phase_3","status":"active","brandName":"PF-02341066","genericName":"PF-02341066","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PF-02341066 is a medication studied in clinical trials for the treatment of Non Small Cell Lung Cancer, Lung Cancer, Adenocarcinoma, NSCLC, and Carcinoma. It is a C-MET inhibitor, as indicated by its use in combination with a PAN-HER inhibitor in a Phase 1 clinical trial.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}